creating knowledge for future

High Quality

Scholarly Publishing
                CAREER NETWORK  
World's one of the largest Research
Career Network
  •     Academic & Industry jobs
  •     Project funding
  •     Visiting faculty positions
  •     Visiting scientist positions
  •     Invited talks
  •     and more...  
Register FREE  
  Global Journal of Biochemistry. Volume 2, Issue 4 (2011) pp. 250-261
  Review Article Free Article
Dysregulation of mTOR pathway component in breast cancer and mTOR inhibitors in breast cancer therapy
  Jun Lin, Xiaochun Bai  
Department of Cell Biology, School of Basic Medical Science, Southern Medical University Guangzhou 510515, China
  In breast cancer, the phosphatidylinositol 3-kinases (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway can be activated by several membrane receptors, including the human epidermal growth factor receptor (HER) family, the insulin-like growth factor (IGF) receptor, and the estrogen receptor (ER), thus plays a critical role in tumorigenesis, progression and development of endocrine resistance. mTOR, the central modulator of this pathway, gained increasing more attention as a potent anti-cancer target. In this review, we summarize the dysregulation of key components of mTOR pathway in breast cancer and their prognostic values, and the clinical application of mTOR inhibitors, with special emphasis on the latest achievement in the recent years.
  Mammalian target of rapamycin; Breast cancer  

  © 2020 Cognizure